• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22336 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     National Institute for Health and Care Excellence (NICE) Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 700
2009     National Institute for Health and Care Excellence (NICE) Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal)
2010     National Institute for Health and Care Excellence (NICE) Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (review of IPG181)
2021     National Institute for Health and Care Excellence (NICE) Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal). NICE technology appraisal guidance 701
2009     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of chronic lymphocytic leukaemia
2010     National Institute for Health and Care Excellence (NICE) Extracranial to intracranial bypass for intracranial atherosclerosis
2021     National Institute for Health and Care Excellence (NICE) Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal). NICE technology appraisal guidance 702
2009     National Institute for Health and Care Excellence (NICE) Tenofovir disoproxil for the treatment of chronic hepatitis B
2010     National Institute for Health and Care Excellence (NICE) Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury
2021     National Institute for Health and Care Excellence (NICE) Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 703
2009     National Institute for Health and Care Excellence (NICE) Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
2010     National Institute for Health and Care Excellence (NICE) Single-incision laparoscopic cholecystectomy
2021     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2005     National Institute for Health and Care Excellence (NICE) Direct C1 lateral mass screw for cervical spine stabilisation
2009     National Institute for Health and Care Excellence (NICE) Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
2010     National Institute for Health and Care Excellence (NICE) Prosthetic intervertebral disc replacement in the cervical spine
2021     National Institute for Health and Care Excellence (NICE) Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 705
2005     National Institute for Health and Care Excellence (NICE) Division of ankyloglossia (tongue-tie) for breastfeeding
2009     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
2010     National Institute for Health and Care Excellence (NICE) Mini-incision surgery for total knee replacement
2021     National Institute for Health and Care Excellence (NICE) Ozanimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 706
2005     National Institute for Health and Care Excellence (NICE) Electrosurgery (diathermy and coblation) for tonsillectomy
2009     National Institute for Health and Care Excellence (NICE) Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
2010     National Institute for Health and Care Excellence (NICE) Macular translocation with 360 degree retinotomy for wet age related macular degeneration
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer. NICE technology appraisal guidance 707
2005     National Institute for Health and Care Excellence (NICE) Endoscopic axillary lymph node retrieval for breast cancer
2009     National Institute for Health and Care Excellence (NICE) Amantadine, oseltamivir and zanamivir for the treatment of influenza
2010     National Institute for Health and Care Excellence (NICE) Limited macular translocation for wet age-related macular degeneration
2021     National Institute for Health and Care Excellence (NICE) Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis. NICE technology appraisal guidance 708
2005     National Institute for Health and Care Excellence (NICE) Retrobulbar irradiation for thyroid eye disease
2009     National Institute for Health and Care Excellence (NICE) Endovascular stent-grafts for the treatment of abdominal aortic aneurysms
2010     National Institute for Health and Care Excellence (NICE) Laparoscopic radical hysterectomy for early stage cervical cancer
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 709
2009     National Institute for Health and Care Excellence (NICE) Cochlear implants for children and adults with severe to profound deafness
2010     National Institute for Health and Care Excellence (NICE) Haemorrhoidal artery ligation
2021     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating atypical haemolytic uraemic syndrome. NICE technology appraisal guidance 710
2010     National Institute for Health and Care Excellence (NICE) Epithelial radiofrequency ablation for Barrett's oesophagus
2021     National Institute for Health and Care Excellence (NICE) Enzalutamide for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 712
2009     National Institute for Health and Care Excellence (NICE) Vagus nerve stimulation for treatment-resistant depression
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 713
2024     National Institute for Health and Care Excellence (NICE) Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal). NICE technology appraisal guidance 965
2010     National Institute for Health and Care Excellence (NICE) Endoscopic saphenous vein harvest for coronary artery bypass grafting
2021     National Institute for Health and Care Excellence (NICE) Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 714
2024     National Institute for Health and Care Excellence (NICE) Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 964
2010     National Institute for Health and Care Excellence (NICE) Transcatheter endovascular closure of perimembranous ventricular septal defect
2021     National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. NICE technology appraisal guidance 715
2024     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2010     National Institute for Health and Care Excellence (NICE) Endoscopic submucosal dissection of lower gastrointestinal lesions
2021     National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 716
2024     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2010     National Institute for Health and Care Excellence (NICE) Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions
2021     National Institute for Health and Care Excellence (NICE) Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 717
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2010     National Institute for Health and Care Excellence (NICE) Arteriovenous crossing sheathotomy for branch retinal vein occlusion
2021     National Institute for Health and Care Excellence (NICE) Ixekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 718
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2010     National Institute for Health and Care Excellence (NICE) Therapeutic endoscopic division of epidural adhesions
2021     National Institute for Health and Care Excellence (NICE) Secukinumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 719
2024     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2010     National Institute for Health and Care Excellence (NICE) Surgical correction of hallux valgus using minimal access techniques
2021     National Institute for Health and Care Excellence (NICE) Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma. NICE technology appraisal guidance 720
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2010     National Institute for Health and Care Excellence (NICE) Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis
2021     National Institute for Health and Care Excellence (NICE) Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 721
2024     National Institute for Health and Care Excellence (NICE) Momelotinib for treating myelofibrosis-related splenomegaly or symptoms. NICE technology appraisal guidance 957
2021     National Institute for Health and Care Excellence (NICE) Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 722
2024     National Institute for Health and Care Excellence (NICE) Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. NICE technology appraisal guidance 956
2021     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 723
2024     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 955
2021     National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer. NICE technology appraisal guidance 724
2024     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 954
2021     National Institute for Health and Care Excellence (NICE) Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 725
2024     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2021     National Institute for Health and Care Excellence (NICE) Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2024     National Institute for Health and Care Excellence (NICE) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2021     National Institute for Health and Care Excellence (NICE) Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2024     National Institute for Health and Care Excellence (NICE) Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2021     National Institute for Health and Care Excellence (NICE) Midostaurin for treating advanced systemic mastocytosis. NICE technology appraisal guidance 728
2024     National Institute for Health and Care Excellence (NICE) Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2021     National Institute for Health and Care Excellence (NICE) Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2024     National Institute for Health and Care Excellence (NICE) Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2021     National Institute for Health and Care Excellence (NICE) Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal). NICE technology appraisal guidance 730
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2008     National Institute for Health and Care Excellence (NICE) Infliximab for the treatment of acute exacerbations of ulcerative colitis
2021     National Institute for Health and Care Excellence (NICE) Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2024     National Institute for Health and Care Excellence (NICE) Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2008     National Institute for Health and Care Excellence (NICE) Febuxostat for the management of hyperuricaemia in people with gout
2021     National Institute for Health and Care Excellence (NICE) Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal). NICE technology appraisal guidance 732
2024     National Institute for Health and Care Excellence (NICE) Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946
2008     National Institute for Health and Care Excellence (NICE) Machine perfusion systems and cold static storage of kidneys from deceased donors
2021     National Institute for Health and Care Excellence (NICE) Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 733
2024     National Institute for Health and Care Excellence (NICE) Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2011     National Institute for Health and Care Excellence (NICE) Aripiprazole for schizophrenia in people aged 15 to 17 years
2008     National Institute for Health and Care Excellence (NICE) Erlotinib for the treatment of non-small cell lung cancer
2021     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2024     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer. NICE technology appraisal guidance 944
2011     National Institute for Health and Care Excellence (NICE) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
2008     National Institute for Health and Care Excellence (NICE) Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin
2021     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2023     National Institute for Health and Care Excellence (NICE) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943